Lexapro (escitalopram) is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age.
%PDF-1.5
%����
It sounds like you have an excellent psychiatrist that is great.
/viewarticle/909960
encoded search term (escitalopram (Lexapro)) and escitalopram (Lexapro) New Data on Birth Defects With Antidepressant Use in PregnancyCan Machine Learning Predict Antidepressant Response?Alzheimer Drug Plus SSRI May Cut Depression, Improve CognitionFive Healthy Lifestyle Choices Tied to Dramatic Cut in Dementia RiskNew Data on Birth Defects With Antidepressant Use in PregnancySupplement Plus Probiotic May Improve Depressive Symptoms COVID-19 Tied to Wide Range of Neuropsychiatric ComplicationsNew Data on Birth Defects With Antidepressant Use in PregnancyAlzheimer Drug Plus SSRI May Cut Depression, Improve CognitionCan Machine Learning Predict Antidepressant Response?Share cases and questions with Physicians on Medscape consult.
Sleep medications, alcohol, barbiturates, and other drugs can interact with Robaxin. provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information. 0000011999 00000 n
0000007175 00000 n
This eMedTV selection talks in detail about the products that can interfere with the muscle relaxant, including the potential results of these interactions.
1050 37
As mentioned above, the use of an SSRI like Lexapro and hydrocodone is a fairly common combination of drugs.
It is used in combination with rest and physical therapy. News
Contact the applicable plan Individual plans may vary 2001
0000005125 00000 n
0000003362 00000 n
trailer
0000008571 00000 n
Robaxin®/Robaxin 750® (methocarbamol) Tablets, USP.
0000003311 00000 n
0000011695 00000 n
0000002033 00000 n
0000013227 00000 n
Methocarbamol is used together with rest and physical therapy to treat skeletal muscle conditions such as pain or injury. Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature. 0000001912 00000 n
Lexapro (escitalopram oxalate) Tablets/Oral Solution NDA 21-323/NDA 21-365 Proposed Labeling Text .
All material on this website is protected by copyright, Copyright © 1994-2020 by WebMD LLC. 0000000016 00000 n
0000006930 00000 n
Please confirm that you would like to log out of Medscape. 0000009772 00000 n
0000002652 00000 n
Methocarbamol is a skeletal muscle relaxant.
It works by blocking nerve impulses (or pain sensations) that are sent to your brain.
National Oceanic and Lexapro Dosage 20 Mg brief discussion of common for anybody who is.
The chemical name of methocarbamol is 3-(2-methoxyphenoxy) -1,2propanediol 1 …
<
DESCRIPTION. 0000013848 00000 n
METHOCARBAMOL (Pronunciation: meth-oh-KAR-ba-mole) • Generic Name: Methocarbamol • Brand Name: Robaxin Relieving muscle pain and discomfort caused by sprains and strains.
2010
0000008658 00000 n
0000017372 00000 n
2001
0000010405 00000 n
methocarbamol Robaxin, Robaxin-750 orphenadrine No brand name currently marketed tizanidine Zanaflex Antipsychotics aripiprazole Abilify, Abilify Maintena, Aristada
0000012653 00000 n
0000005771 00000 n
https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvbGV4YXByby1lc2NpdGFsb3ByYW0tMzQyOTYx 1050 0 obj
<>
endobj
0000008526 00000 n
0000003272 00000 n
0000016520 00000 n
A woman with a genetic predisposition to pheochromocytoma was receiving venlafaxine, which can increase plasma metanephrine levels. Indicated for acute and maintenance treatment of major depressive disorder (MDD) 10 mg PO qDay; may increase to 20 mg/day after 1 weekIndicated for acute treatment of generalized anxiety disorder (GAD) 10 mg PO qDay; may increase to 20 mg/day after 1 week; maintain at lowest effective dose and assess need of therapy periodically if extended therapy required10 mg PO qDay; may increase to 20 mg/day after 1 week; maintain at lowest effective dose and assess need of therapy periodically if extended therapy requiredSecondary to Depression: 5-20 mg PO over 8 week periodSecondary to panic disorder in women: 5-10 mg PO over 8 week period10 mg PO qDay; may increase to 20 mg PO qDay after 4 weeks if symptoms not adequately controlledFor extended therapy, maintain at lowest effective dose and assess periodically the need for continued therapy≥12 years: 10 mg PO qDay; may increase dose after at least 3 weeks; not to exceed 20 mg/dayFor extended therapy, maintain at lowest effective dose and assess periodically the need for continued therapy10 mg/day is recommended for most elderly; no additional benefits seen at 20 mg/day doseThe elderly are more prone to SSRI/SNRI-induced hyponatremiaBlood and lymphatic system disorders: Anemia, agranulocytosis, aplastic anemia, hemolytic anemia, idiopathic thrombocytopenia purpura, leukopenia, thrombocytopeniaCardiac disorders: Atrial fibrillation, bradycardia, cardiac failure, myocardial infarction, tachycardia, torsades de pointes, ventricular arrhythmia, ventricular tachycardiaEndocrine disorders: Diabetes mellitus, hyperprolactinemia, SIADHEye disorders: Angle closure glaucoma, diplopia, mydriasis, visual disturbanceGastrointestinal disorder: Dysphagia, gastrointestinal hemorrhage, gastroesophageal reflux, pancreatitis, rectal hemorrhageGeneral disorders and administration site conditions: Abnormal gait, asthenia, edema, fall, feeling abnormal, malaiseHepatobiliary disorders: Fulminant hepatitis, hepatic failure, hepatic necrosis, hepatitisImmune system disorders: Allergic reaction, anaphylaxisInvestigations: Bilirubin increased, decreased weight, QT prolongation, hepatic enzymes increased, hypercholesterolemia, INR increased, prothrombin decreasedMetabolism and nutrition disorders: Hyperglycemia, hypoglycemia, hypokalemia, hyponatremiaMusculoskeletal and connective tissue disorders: Muscle cramp, muscle stiffness, muscle weakness, rhabdomyolysisNervous system disorders: Akathisia, amnesia, ataxia, choreoathetosis, cerebrovascular accident, dysarthria, dyskinesia, dystonia, extrapyramidal disorders, grand mal seizures (or convulsions), myoclonus, nystagmus, Parkinsonism, restless legs, seizures, syncope, tardive dyskinesia, tremorPregnancy, puerperium and perinatal conditions: Spontaneous abortionPsychiatric disorders: Acute psychosis, aggression, agitation, anger, anxiety, apathy, completed suicide, confusion, depersonalization, depression aggravated, delirium, delusion, disorientation, feeling unreal, hallucinations (visual and auditory), mood swings, nervousness, nightmare, panic reaction, paranoia, restlessness, self-harm or thoughts of self-harm, suicide attempt, suicidal ideation, suicidal tendency Renal and urinary disorders: Acute renal failure, dysuria, urinary retentionReproductive system and breast disorders: Menorrhagia, priapismRespiratory, thoracic and mediastinal disorders: Dyspnea, epistaxis, pulmonary embolism, pulmonary hypertension of the newbornSkin and SC tissue disorders: Alopecia, angioedema, dermatitis, ecchymosis, erythema multiforme, photosensitivity reaction, Stevens Johnson syndrome, toxic epidermal necrolysis, urticariaVascular Disorders: Deep vein thrombosis, flushing, hypertensive crisis, hypotension, orthostatic hypotension, phlebitis, thrombosisConflicting evidence regarding use of SSRIs during pregnancy and increased risk of persistent pulmonary hypertension of the newborn, or PPHN (see Pregnancy)In neonates exposed to SNRIs/SSRIs late in third trimester: risk of complications such as feeding difficulties, irritability, and respiratory problemsPrior to initiating treatment, screen patients for any personal or family history of bipolar disorder, mania, or hypomaniaCaution with seizure disorder, bipolar mania, severe renal impairment; not FDA approved for the treatment of bipolar depressionSNRIs/SSRIs have been associated with the development of SIADH; hyponatremia has been reported rarelyActivation of mania/hypomania reported in a small proportion of patients with major affective disorders treated with citalopram and other marketed drugs effective in treatment of major depressive disorderMay worsen psychosis in some patients and precipitate a shift to mania or hypomania in patients with bipolar disorderConsider changing therapeutic regimen, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviorsRisk of mydriasis; may trigger angle closure attack in patients with angle closure glaucoma with anatomically narrow angles without a patent iridectomyBone fractures are associated with antidepressant therapy; consider the possibility of a fracture in patients with unexplained bone pain, swelling, or bruisingPrescribe the smallest quantity of tablets consistent with good patient care and alert family or caregiver to monitor for emergence of suicidality and associated behaviors (anxiety, agitation, panic attacks, insomnia, hostility, akathisia, impulsivity, irritability)SSRIs/SNRIs increase risk of abnormal bleeding (further increased if concomitant aspirin, NSAIDs or anticoagulants, or hemorrhagic diathesis)Prolongation of QT interval and ventricular arrhythmias reported, especially in female patients with preexisting QT prolongation or other risk factorsRisk of cognitive and motor function impairment; use caution when operating heavy machineryUse with caution in patients with history of seizure disorders or conditions predisposing to seizures including brain damage and alcoholismGradually taper dose before discontinuation; abrupt discontinuation may cause dysphoric mood, dizziness, sensory disturbances, agitation, confusion, anxiety, headache, insomnia, tinnitus, seizures, irritabilityThere are no adequate and well-controlled studies in pregnant women; therefore, use during pregnancy only if the potential benefit justifies the potential risk to the fetusIn some cases, the clinical picture is consistent with serotonin syndrome Limited data from women taking 10-20 mg escitalopram showed that exclusively breast-fed infants receive a ~3.9% of the maternal weight-adjusted dose of escitalopram and 1.7% of the maternal weight-adjusted dose of desmethylcitalopramCaution should be exercised and breastfeeding infants should be observed for adverse reactions when administered to a nursing womanA: Generally acceptable.